(Q54240617)
Statements
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. (English)
1 reference
1 reference
Didier Meulendijks
1 reference
Wolfgang Jacob
1 reference
Maria Martinez-Garcia
1 reference
Alvaro Taus
1 reference
Martijn P Lolkema
1 reference
Emile E Voest
1 reference
Marlies H G Langenberg
1 reference
Tania Fleitas Kanonnikoff
1 reference
Andres Cervantes
1 reference
Maja J De Jonge
1 reference
Stefan Sleijfer
1 reference
Morten Mau Soerensen
1 reference
Marlene Thomas
1 reference
Maurizio Ceppi
1 reference
Georgina Meneses-Lorente
1 reference
Ian James
1 reference
Celine Adessi
1 reference
Francesca Michielin
1 reference
Keelara Abiraj
1 reference
Birgit Bossenmaier
1 reference
Jan H M Schellens
1 reference
Martin Weisser
1 reference
13 October 2015
1 reference
22
1 reference
877-885
1 reference
4
1 reference
Identifiers
1 reference